US Patent Issued to Mayo Foundation for Medical Education and Research on July 22 for "Methods for treating VEGF-expressing cancer using preformed nanoparticle complexes comprising albumin-bound paclitaxel and bevacizumab" (Minnesota Inventors)

ALEXANDRIA, Va., July 23 -- United States Patent no. 12,364,754, issued on July 22, was assigned to Mayo Foundation for Medical Education and Research (Rochester, Minn.).

"Methods for treating VEGF-expressing cancer using preformed nanoparticle complexes comprising albumin-bound paclitaxel and bevacizumab" was invented by Svetomir N. Markovic (Rochester, Minn.) and Wendy K. Nevala (Rochester, Minn.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed herein are compositions comprising nanoparticle complexes comprising albumin-bound paclitaxel and an anti-VEGF antibody, wherein the ratio of albumin-paclitaxel to antibody is between 2:1 and 1:25. Additionally disclosed herein are methods using the composit...